Delcath Systems Reports Strong FY25 Results, Achieves Net Income, and Issues Positive 2026 Revenue Guidance

summarizeSummary

Delcath Systems reported strong full-year 2025 financial results, including a shift to net income and positive adjusted EBITDA, alongside optimistic 2026 revenue guidance and significant product volume growth.

check_boxKey Events

• Strong Full-Year 2025 Financial Performance

  Delcath Systems reported full-year 2025 revenue of $85.2 million, a significant increase from $37.2 million in 2024. The company achieved a net income of $2.7 million for the full year, reversing a $26.4 million net loss in the prior year, and reported positive adjusted EBITDA of $25.1 million.

• Positive 2026 Revenue Guidance Issued

  The company provided full-year 2026 financial guidance, projecting total revenue of at least $100 million. This reflects an anticipated increase in HEPZATO KIT volume of at least 20% over 2025, with gross margins expected to be in the range of 84% to 87%.

• Significant Product Volume Growth and Clinical Progress

  Delcath reported approximately 140% growth in HEPZATO procedure volume in 2025 compared to 2024. Additionally, the company announced the publication of positive results from the Phase 2 CHOPIN trial, demonstrating significant improvement in one-year progression-free survival when CHEMOSAT is sequenced with checkpoint inhibitors.

• Solid Balance Sheet and Share Buyback Program

  As of December 31, 2025, Delcath Systems had a strong cash and short-term investments balance of $91.0 million and no debt. The company also repurchased 628,572 common shares for $6.0 million through December 31, 2025, under its approved $25 million share buyback program.

auto_awesomeAnalysis

Delcath Systems has reported a strong financial turnaround, achieving full-year net income of $2.7 million in 2025, a significant improvement from a $26.4 million net loss in the prior year. This finalizes the preliminary positive results reported on January 12, 2026, and provides a clear, optimistic outlook for 2026 with revenue guidance of at least $100 million. The company's robust revenue growth, positive adjusted EBITDA, and healthy cash position with no debt indicate a solid financial foundation. Furthermore, the substantial growth in HEPZATO procedure volume and positive clinical trial data reinforce the commercial potential and efficacy of its key product, suggesting continued momentum for the company.